119 related articles for article (PubMed ID: 25683851)
1. Glucose conjugation of anti-HIV-1 oligonucleotides containing unmethylated CpG motifs reduces their immunostimulatory activity.
Reyes-Darias JA; Sánchez-Luque FJ; Morales JC; Pérez-Rentero S; Eritja R; Berzal-Herranz A
Chembiochem; 2015 Mar; 16(4):584-91. PubMed ID: 25683851
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 replication by triple-helix-forming phosphorothioate oligonucleotides targeted to the polypurine tract.
Tsukahara S; Suzuki J; Hiratou T; Takai K; Koyanagi Y; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1997 Apr; 233(3):742-7. PubMed ID: 9168925
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human immunodeficiency virus type 1 replication by P-stereodefined oligo(nucleoside phosphorothioate)s in a long-term infection model.
Inagawa T; Nakashima H; Karwowski B; Guga P; Stec WJ; Takeuchi H; Takaku H
FEBS Lett; 2002 Sep; 528(1-3):48-52. PubMed ID: 12297278
[TBL] [Abstract][Full Text] [Related]
4. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
Lavigne C; Yelle J; Sauve G; Thierry AR
AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
[TBL] [Abstract][Full Text] [Related]
5. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.
Yamaguchi K; Papp B; Zhang D; Ali AN; Agrawal S; Byrn RA
AIDS Res Hum Retroviruses; 1997 May; 13(7):545-54. PubMed ID: 9135872
[TBL] [Abstract][Full Text] [Related]
6. Anti-human immunodeficiency virus type 1 of a two-strand-system targeted to the polypurine tract.
Hiratou T; Miyano-Kurosaki N; Tsukahara S; Tamura Y; Takai K; Yamamoto N; Takaku H
Int J Mol Med; 2000 Feb; 5(2):125-32. PubMed ID: 10639589
[TBL] [Abstract][Full Text] [Related]
7. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
[TBL] [Abstract][Full Text] [Related]
8. Application of antisense technology to therapeutics.
Heidenreich O; Kang SH; Xu X; Nerenberg M
Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
[TBL] [Abstract][Full Text] [Related]
9. Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication.
Lavigne C; Yelle J; Sauvé G; Thierry AG
AAPS PharmSci; 2001; 3(1):E7. PubMed ID: 11741258
[TBL] [Abstract][Full Text] [Related]
10. Antisense phosphorothioate oligonucleotides targeted to the human chemokine receptor CXCR4.
Kusunoki A; Miyano-Kurosaki N; Kimura T; Takai K; Yamamoto N; Gushima H; Takaku H
Nucleosides Nucleotides Nucleic Acids; 2000; 19(10-12):1709-19. PubMed ID: 11200267
[TBL] [Abstract][Full Text] [Related]
11. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
[TBL] [Abstract][Full Text] [Related]
12. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.
Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960
[TBL] [Abstract][Full Text] [Related]
13. G-Quadruplex Structure Improves the Immunostimulatory Effects of CpG Oligonucleotides.
Hoshi K; Yamazaki T; Sugiyama Y; Tsukakoshi K; Tsugawa W; Sode K; Ikebukuro K
Nucleic Acid Ther; 2019 Aug; 29(4):224-229. PubMed ID: 30835633
[TBL] [Abstract][Full Text] [Related]
14. HIV RNA dimerisation interference by antisense oligonucleotides targeted to the 5' UTR structural elements.
Reyes-Darias JA; Sánchez-Luque FJ; Berzal-Herranz A
Virus Res; 2012 Oct; 169(1):63-71. PubMed ID: 22820401
[TBL] [Abstract][Full Text] [Related]
15. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by a two-strand system (FTFOs) targeted to the polypurine tract.
Hiratou T; Tsukahara S; Miyano-Kurosaki N; Takai K; Yamamoto N; Takaku H
FEBS Lett; 1999 Jul; 456(1):186-90. PubMed ID: 10452555
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides.
Park WS; Miyano-Kurosaki N; Abe T; Takai K; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 2000 Apr; 270(3):953-60. PubMed ID: 10772932
[TBL] [Abstract][Full Text] [Related]
18. Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates.
Boado RJ; Pardridge WM
Bioconjug Chem; 1994; 5(5):406-10. PubMed ID: 7849069
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 replication by foldback triple-helix forming oligonucleotides.
Hiratou T; Tsukahara S; Takai K; Koyanagi Y; Yamamoto N; Takaku H
Nucleic Acids Symp Ser; 1997; (37):221-2. PubMed ID: 9586079
[TBL] [Abstract][Full Text] [Related]
20. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity.
Zhao Q; Yu D; Agrawal S
Bioorg Med Chem Lett; 1999 Dec; 9(24):3453-8. PubMed ID: 10617090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
